Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.
作者信息
Hassan Sajjad, West Kamille A, Conry-Cantilena Kathleen, De Giorgi Valeria
机构信息
Department of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Transfusion. 2022 Feb;62(2):483-492. doi: 10.1111/trf.16751. Epub 2021 Dec 3.
Abstract
摘要
相似文献
1
Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.美国新冠疫情演变阶段恢复期血浆采集面临的监管挑战
Transfusion. 2022 Feb;62(2):483-492. doi: 10.1111/trf.16751. Epub 2021 Dec 3.
2
Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.8000 例美国首次恢复期血浆捐献者中 SARS-CoV-2 抗体的纵向分析。
Transfusion. 2021 Apr;61(4):1141-1147. doi: 10.1111/trf.16291. Epub 2021 Feb 22.
3
COVID-19 convalescent plasma from Norwegian blood donors.来自挪威献血者的新冠康复期血浆。
Tidsskr Nor Laegeforen. 2022 Jun 13;142(9). doi: 10.4045/tidsskr.22.0057. Print 2022 Jun 14.
4
Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.从恢复期血浆中生产抗 SARS-CoV-2 超免疫球蛋白。
Transfusion. 2021 Jun;61(6):1705-1709. doi: 10.1111/trf.16378. Epub 2021 Mar 22.
5
Deployment of convalescent plasma for the prevention and treatment of COVID-19.恢复期血浆在 COVID-19 预防和治疗中的应用。
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
6
Coronavirus Disease 2019 Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample.2019 年冠状病毒疾病恢复期血浆在美国的利用：来自国家住院患者样本的数据。
Clin Infect Dis. 2023 Jul 26;77(2):237-241. doi: 10.1093/cid/ciad185.
7
Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.SARS-CoV-2 血清学检测在使用 FDA 阈值鉴定高滴度 COVID-19 恢复期血浆中的相关性有限。
Microbiol Spectr. 2022 Aug 31;10(4):e0115422. doi: 10.1128/spectrum.01154-22. Epub 2022 Jul 5.
8
Convalescent Plasma and COVID-19.康复期血浆与2019冠状病毒病
JAMA. 2020 Aug 4;324(5):524. doi: 10.1001/jama.2020.10699.
9
Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.来自新冠病毒感染康复者的捐赠者血浆——优先事项问题
Transfus Clin Biol. 2020 Aug;27(3):167-168. doi: 10.1016/j.tracli.2020.05.002. Epub 2020 Jun 12.
10
Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.康复期血浆捐献者体内抗SARS-CoV-2血清抗体随时间下降。
Transfusion. 2021 Feb;61(2):651-654. doi: 10.1111/trf.16172.
引用本文的文献
1
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review.抗新冠病毒的高效价免疫血浆和免疫球蛋白：叙述性综述
Life (Basel). 2024 Feb 1;14(2):214. doi: 10.3390/life14020214.
本文引用的文献
1
Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report.康复期血浆疗法对免疫功能低下的新冠肺炎患者的疗效：一例报告
Clin Infect Pract. 2021 Nov;12:100096. doi: 10.1016/j.clinpr.2021.100096. Epub 2021 Sep 1.
2
Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.免疫功能低下患者的恢复期血浆介导的 SARS-CoV-2 病毒清除，无 B 细胞恢复。
Int J Mol Sci. 2021 Aug 18;22(16):8902. doi: 10.3390/ijms22168902.
3
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.SARS-CoV-2 从高中和性的 COVID-19 恢复期血浆中逃逸。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2103154118.
4
Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection.自然获得的 SARS-CoV-2 免疫力在感染后可持续长达 11 个月。
J Infect Dis. 2021 Oct 28;224(8):1294-1304. doi: 10.1093/infdis/jiab295.
5
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.COVID-19 患者住院期间的恢复期血浆治疗（RECOVERY）：一项随机对照、开放标签、平台试验。
Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14.
6
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.一项关于恢复期血浆治疗成人重症 COVID-19 的随机、双盲、对照临床试验。
J Clin Invest. 2021 Jul 1;131(13). doi: 10.1172/JCI150646.
7
COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?COVID-19 恢复期血浆作为免疫功能低下患者的长期治疗方法？
Transfus Clin Biol. 2021 Aug;28(3):264-270. doi: 10.1016/j.tracli.2021.04.004. Epub 2021 Apr 24.
8
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19.恢复期血浆输注对免疫功能低下的COVID-19患者的潜在益处。
Lancet Microbe. 2021 Apr;2(4):e138. doi: 10.1016/S2666-5247(21)00030-6. Epub 2021 Mar 30.
9
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.SARS-CoV-2 变体 B.1.351 和 P.1 逃避中和抗体。
Cell. 2021 Apr 29;184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036. Epub 2021 Mar 20.
10
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.SARS-CoV-2 501Y.V2 逃避恢复期血浆中和作用。
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
Zotero 插件